Meloxicam (MLX) is a poorly soluble drug exhibiting strong hydrophobicity. This combination of properties makes dissolution enhancement by particle size reduction ineffective; therefore, combined formulation approaches are required. Various approaches were investigated in this study, including milling, solid dispersions, and self-emulsified lipid formulations. Whereas milling studies of MLX and its co-milling with various polymers have been reported in recent literature, this study is focused on investigating the dissolution kinetics of particulate formulations obtained by co-milling MLX with sodium lauryl sulfate (SLS) in a planetary ball mill with 5-25 wt.% SLS content. The effects of milling time and milling ball size were also investigated. No significant reduction in drug crystallinity was observed under the investigated milling conditions according to XRD data. For the dissolution study, we used an open-loop USP4 dissolution apparatus, and recorded dissolution profiles were fitted according to the Weibull model. The Weibull parameters and a novel criterion-surface utilization factor-were used to evaluate and discuss the drug release from the perspective of drug particle surface changes throughout the dissolution process. The most effective co-milling results were achieved using smaller balls (2 mm), with a co-milling time of up to 15 min SLS content of up to 15 wt.% to increase the dissolution rate by approximately 100 times relative to the physical mixture reference. The results suggest that for hydrophobic drugs, particle performance during dissolution is very sensitive to surface properties and not only to particle size. Co-milling with SLS prepares the surface for faster drug release than that achieved with direct mixing.

Department of Organic Technology University of Chemistry and Technology Prague Technická 5 166 28 Prague Czech Republic

Zobrazit více v PubMed

Boldyrev V.V. Mechanochemistry and mechanical activation of solids. Russ. Chem. Rev. 2006;75:177–189. doi: 10.1070/RC2006v075n03ABEH001205. DOI

Khadka P., Roa J., Kim H., Kim I., Kim J.T., Kim H., Cho J.M., Yun G., Lee J. Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability. Asian J. Pharm. Sci. 2014;9:304–316. doi: 10.1016/j.ajps.2014.05.005. DOI

Chu K.R., Lee E., Jeong S.H., Park E.S. Effect of particle size on the dissolution behaviors of poorly water-soluble drugs. Arch. Pharm. Res. 2012;35:1187–1195. doi: 10.1007/s12272-012-0709-3. PubMed DOI

Loh Z.H., Samanta A.K., Heng P.W.S. Overview of milling techniques for improving the solubility of poorly water-soluble drugs. Asian J. Pharm. Sci. 2015;10:255–274. doi: 10.1016/j.ajps.2014.12.006. DOI

Szafraniec J., Antosik A., Knapik-Kowalczuk J., Kurek M., Syrek K., Chmiel K., Paluch M., Jachowicz R. Planetary ball milling and supercritical fluid technology as a way to enhance dissolution of bicalutamide. Int. J. Pharm. 2017;533:470–479. doi: 10.1016/j.ijpharm.2017.03.078. PubMed DOI

Chaudhari S.P., Dugar R.P. Application of surfactants in solid dispersion technology for improving solubility of poorly water soluble drugs. J. Drug Deliv. Sci. Technol. 2017;41:68–77. doi: 10.1016/j.jddst.2017.06.010. DOI

Slamova M., Prausova K., Epikaridisova J., Brokesova J., Kuentz M., Patera J., Zamostny P. Effect of co-milling on disso-lution rate of poorly soluble drugs. Int. J. Pharm. 2021;597:120312. doi: 10.1016/j.ijpharm.2021.120312. PubMed DOI

Yazdanian M., Briggs K., Jankovsky C., Hawi A. The “high solubility” definition of the current FDA Guidance on Bio-pharmaceutical Classification System may be too strict for acidic drugs. Pharm. Res. 2004;21:293–299. doi: 10.1023/B:PHAM.0000016242.48642.71. PubMed DOI

Sheth A.R., Lubach J.W., Munson E.J., Muller F.X., Grant D.J. Mechanochromism of piroxicam accompanied by intermo-lecular proton transfer probed by spectroscopic methods and solid-phase changes enhancer. J. Am. Chem. Soc. 2005;127:6641–6651. doi: 10.1021/ja045823t. PubMed DOI

Gupta M.K., Vanwert A., Bogner R.H. Formation of physically stable amorphous drugs by milling with Neusilin. J. Pharm. Sci. 2003;92:536–551. doi: 10.1002/jps.10308. PubMed DOI

Samprasit W., Akkaramongkolporn P., Ngawhirunpat T., Rojanarata T., Opanasopit P. Formulation and evaluation of meloxicam oral disintegrating tablet with dissolution enhanced by combination of cyclodextrin and ion exchange resins. Drug Dev. Ind. Pharm. 2015;41:1006–1016. doi: 10.3109/03639045.2014.922573. PubMed DOI

Kürti L., Kukovecz Á., Kozma G., Ambrus R., Deli M.A., Szabó-Révész P. Study of the parameters influencing the co-grinding process for the production of Meloxicam nanoparticles. Powder Technol. 2011;212:210–217. doi: 10.1016/j.powtec.2011.05.018. DOI

Agustin R., Oktavia L., Fitriani L., Zaini E. Preparation and characterization of co-grinding tablet of Meloxicam with PVP K-30. Pharm. Lett. 2016;8:166–169.

Zaini E., Witarsa A.S., Agustin R. Enhancement of dissolution rate of Meloxicam by co-grinding technique using Hydroxy-propyl methylcellulose. J. Chem. Pharm. Res. 2014;6:263–267.

Etman M., Shekedef M., Nada A., Ismail A. In vitro and In vivo Evaluation of Tablets Containing Meloxicam- PEG 6000 Ball-Milled Co-Ground Mixture. J. Appl. Pharm. 2017;7:31–39. doi: 10.7324/JAPS.2017.70306. DOI

Bartos C., Szabó-Révész P., Bartos C., Katona G., Jójárt-Laczkovich O., Ambrus R. The Effect of an optimized wet milling technology on the crystallinity, Morphology and Dissolution Properties of Micro- and Nanonized Meloxicam. Molecules. 2016;21:507. doi: 10.3390/molecules21040507. PubMed DOI PMC

Brokesova J., Slamova M., Zamostny P., Kuentz M., Koktan J., Krejcik L., Vranikova B., Svacinova P., Sklubalova Z. Mechanistic study of dissolution enhancement by interactive mixtures of chitosan with meloxicam as model. Eur. J. Pharm. Sci. 2022;169:106087. doi: 10.1016/j.ejps.2021.106087. PubMed DOI

Marinko N., Zamostny P. Meloxicam Carrier Systems Having Enhanced Release and Aqueous Wettability Prepared Using Micro-suspensions in Different Liquid Media. Aaps Pharmscitech. 2020;21:155. doi: 10.1208/s12249-020-01701-4. PubMed DOI

Dehghan M.H.G., Jafar M. Improving Dissolution of Meloxicam Using Solid Dispersions. Iranian J. Pharm. Res. 2006;4:231–238. doi: 10.22037/ijpr.2010.682. DOI

Aejaz A., Jafar M., Dehghan M.H.G., Adil Shareef S. Meloxicam-PVP-SLS ternary dispersion systems: In-vitro and in-vivo evaluation. Int. J. Pharm. Pharm. Sci. 2010;2:182–190.

Maggi L., Bruni G., Maietta M., Canobbio A., Cardini A., Conte U., II Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: Co-milling. Int. J. Pharm. 2013;454:568–572. doi: 10.1016/j.ijpharm.2013.06.085. PubMed DOI

Maggi L., Canobbio A., Bruni G., Musitelli G., Conte U. Improvement of the dissolution behavior of gliclazide, a slightly soluble drug, using solid dispersions. J. Drug Deliv. Sci. Technol. 2015;26:17–23. doi: 10.1016/j.jddst.2015.01.002. DOI

Dressman J., Krämer J. Pharmaceutical Dissolution Testing. Taylor & Francis Group, LLC; New York, NY, USA: 2005.

Ramteke K., Dighe P., Kharat A., Patil S. Mathematical Models of Drug Dissolution: A Review. Sch. Acad. J. Pharm. 2014;3:388–396.

Papadopoulou V., Kosmidis K., Vlachou M., Maderas P. On the use of the Weibull function for the discernment of drug release mechanisms. Int. J. Pharm. 2006;309:44–50. doi: 10.1016/j.ijpharm.2005.10.044. PubMed DOI

Zamostny P., Belohlav Z. A software for regression analysis of kinetic data. Comput. Chem. 1999;23:479–485. doi: 10.1016/S0097-8485(99)00024-8. DOI

Van Eerdenbrugh B., Van den Mooter G., Augustijns P. Top-down production of drug nanocrystals: Nanosuspension stabi-lization, miniaturization and transformation into solid products. Int. J. Pharm. 2008;364:64–75. doi: 10.1016/j.ijpharm.2008.07.023. PubMed DOI

Saharan V.A., Kukkar V., Kataria M., Kharb V., Choudhury P.K. Ordered mixing: Mechanism, process and applications in pharmaceutical formulations. Asian J. Pharm. Sci. 2008;3:240–259.

Varghese S., Ghoroi C. Improving the wetting and dissolution of ibuprofen using solventless co-milling. Int. J. Pharm. 2017;533:145–155. doi: 10.1016/j.ijpharm.2017.09.062. PubMed DOI

Kale K., Hapgood K., Stewart P. Drug agglomeration and dissolution—What is the influence of powder mixing? Eur. J. Pharm. Biopharm. 2009;72:156–164. doi: 10.1016/j.ejpb.2008.12.015. PubMed DOI

Lachiver E.D., Abatzoglou N., Cartilier L., Simard J.S. Agglomeration tendency in dry pharmaceutical granular systems. Eur. J. Pharm. Biopharm. 2006;64:193–199. doi: 10.1016/j.ejpb.2006.04.005. PubMed DOI

Dokoumetzidis A., Papadopoulou V., Macheras P. Analysis of dissolution data using modified versions of Noyes-Whitney equation and the Weibull function. Pharm. Res. 2006;23:256–261. doi: 10.1007/s11095-006-9093-3. PubMed DOI